Abstracts Archive - Page 1418 of 2607 - ACR Meeting Abstracts

Abstract Number: 461 • 2017 ACR/ARHP Annual Meeting
Additions to Methotrexate with Conventional and Biologic Dmards in Rheumatoid Arthritis: Are There Differences in Subsequent Time to Treatment Failure?
Sasha Bernatsky¹, Orit Schieir², Cristiano S. Moura³, Marie-France Valois⁴, Susan J. Bartlett⁵, Carol A Hitchon⁶, Janet E. Pope⁷, Gilles Boire⁸, Boulos Haraoui⁹, Edward C. Keystone¹⁰, Diane Tin¹¹, Carter Thorne¹² and Vivian P. Bykerk¹³, ¹Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²McGill University, Montreal, ON, Canada, ³1Division of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁸Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁹Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ¹⁰University of Toronto, Toronto, ON, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²University of Toronto, Newmarket, ON, Canada, ¹³2-005, Mt Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Our objective was to compare RA treatment strategies with conventional and biologic DMARDs after an initial MTX strategy was ineffective or associated with a…
Abstract Number: 462 • 2017 ACR/ARHP Annual Meeting
ABP 710: Matching Critical Biological Functions with Infliximab
Robert Sandrock¹, Palanisamy Kanakaraj² and Scott Kuhns¹, ¹Amgen, Inc., Thousand Oaks, CA, ²Amgen, Inc., Cambridge, MA
Background/Purpose: ABP 710 is being developed as a biosimilar to infliximab, a recombinant chimeric monoclonal antibody that binds tumor necrosis factor alpha (TNFa) and inhibits…
Abstract Number: 463 • 2017 ACR/ARHP Annual Meeting
Certolizumab Pegol for Fatigue in Chronic Inflammatory Rheumatic Diseases: A Meta-Analysis
Yesim Ozguler¹, Sinem Nihal Esatoglu¹, Guzin Karatemiz¹, Ali Ugur Unal², Gul Guzelant¹, Elif Dincses³, Mustafa Erdogan¹, Sema Kaymaz Tahra² and Gulen Hatemi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Departement of Internal Medicine, Division of Rheumatology, Marmara University, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey
Background/Purpose: Fatigue is an important problem that impairs life quality in patients with rheumatic diseases. Although fatigue is often associated with disease activity, only a…
Abstract Number: 464 • 2017 ACR/ARHP Annual Meeting
Value of Matrix Metalloproteinase-3 Regarding Prediction for Joint Destruction at 1 Year Is Different between Sexes in Patients with Rheumatoid Arthritis
Yutaro Yamada¹, Kentaro Inui², Tadashi Okano³, Yuko Sugioka¹, Kenji Mamoto⁴, Kazuki Orita⁵, Tatsuya Koike⁶, Masahiro Tada⁷ and Hiroaki Nakamura³, ¹Orthopedic surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Orhopedic surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ³Orthopaedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁴Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁵Orthopedics, Shirahama hamayu Hospital, Shirahama, Japan, ⁶Center for Senile Degenerative Disorders, Osaka City University Medical School, Osaka, Japan, ⁷Orthopedic Surgery, Osaka City General Hospital, Osaka, Japan
Background/Purpose: Serum level of MMP-3 rises by synovial inflammation in patients with rheumatoid arthritis (RA). It destroys articular cartilage such as proteoglycans so that it…
Abstract Number: 465 • 2017 ACR/ARHP Annual Meeting
Basement Membrane Remodeling in Rheumatoid Arthritis Associates with Disease Activity, Response to IL-6 Inhibitor Treatment and Radiographic Progression: Analysis of Two Phase III Clinical Trials
Natasja Stæhr Gudman¹, Pernille Juhl¹, Christian S. Thudium², Peter Junker³, Anne Sofie Siebuhr⁴, Inger Byrjalsen¹, Morten Karsdal⁵ and Anne C. Bay-Jensen⁴, ¹Nordic Bioscience, Herlev, Denmark, ²Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ³Department of Rheumatology C, Odense University Hospital, Odense, Denmark, ⁴Rheumatology, Nordic Bioscience, Herlev, Denmark, ⁵Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is associated with neovascularization of the synovial membrane and increased risk of cardiovascular co-morbidity. The extra cellular matrix below the endothelial…
Abstract Number: 466 • 2017 ACR/ARHP Annual Meeting
Plasma Cytokines at Diagnosis May Predict Non-Response to Methotrexate in Patients with Early Rheumatoid Arthritis
Martin Pelletier¹, Paul R. Fortin^1,2, Marie-Pier Longchamps¹, Geneviève Parent¹, Hadrien Benk-Fortin¹, Anne-Sophie Julien³, Nathalie Amiable¹, Emmanuelle Rollet-Labelle¹, Laetitia Michou², Louis Bessette² and Philippe A. Tessier¹, ¹Infectious Diseases and Immunity Research Division, CHU de Québec-Université Laval Research Center, Québec, QC, Canada, ²Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada, ³Clinical Research Platform, CHU de Québec-Université Laval Research Center, Québec, QC, Canada
Background/Purpose: Methotrexate (MTX) is the first line treatment for patients with rheumatoid arthritis (RA). For over 30% of patients, MTX fails to diminish DAS28 score…
Abstract Number: 467 • 2017 ACR/ARHP Annual Meeting
Smoking and Opioid Use Is Associated with Symptom Severity in Rheumatoid Arthritis
Angela Karellis^1,2, Emmanouil Rampakakis³, John S. Sampalis^1,4, Martin Cohen⁵, Michael Starr⁵, Peter Ste-Marie⁶, Yoram Shir⁶, Mark Ware⁶ and MaryAnn FitzCharles^6,7, ¹JSS Medical Research, St-Laurent, QC, Canada, ²Department of Surgery, McGill University, Montreal, QC, Canada, ³JSS Medical Research, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁶Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ⁷Rheumatology, McGill University, Montreal, QC, Canada
Smoking and Opioid Use Is Associated with Symptom Severity in Rheumatoid ArthritisBackground/Purpose: Cigarette smoking, both current and past, is a risk for incident rheumatoid arthritis…
Abstract Number: 468 • 2017 ACR/ARHP Annual Meeting
Initiation of Biologic Disease Modifying Antirheumatic Drug Therapy and Associated Changes in Disease Activity Measures in Routine Clinical Practice: Findings from a Large Contemporaneous Real World Cohort
Zhaohui Su¹, Tom Brecht¹, Anna Lafontant¹, Costas Boussios¹, Francis O’Donovan², Charles Kekeh², Kathryn Starzyk¹, Richard Gliklich³ and Vandana Menon¹, ¹Research, OM1, Inc, Cambridge, MA, ²Data Science, OM1, Inc, Cambridge, MA, ³OM1, Inc, Cambridge, MA
Background/Purpose: While many clinical trials provide direct comparisons between biologic disease modifying antirheumatic drugs (bDMARD) and nonbiologic DMARD (nDMARD), there is a need for additional…
Abstract Number: 469 • 2017 ACR/ARHP Annual Meeting
Effect of Patient Involvement in Treatment Decision Making on Disease Outcomes in Rheumatoid Arthritis in the USA
Richard Hutchings¹, Shailja Panchal² and Elizabeth Baynton¹, ¹Ipsos Healthcare, London, United Kingdom, ²Ipsos Healthcare, New York, NY
Background/Purpose: ACR guidelines for treating Rheumatoid Arthritis (2015) suggest that treatment decisions should be made by physicians and patients through a shared decision-making process taking…
Abstract Number: 470 • 2017 ACR/ARHP Annual Meeting
Clinical Response to the First Biologic in Rheumatoid Arthritis Patients with Moderate Disease in a Real World Clinical Cohort
Xiuying Li, Angela Cesta, Mohammad Movahedi and Claire Bombardier, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: While most randomized trials assess the effectiveness of biologic DMARDs (bDMARDs) in rheumatoid arthritis (RA) patients with high disease activity, in the real world…
Abstract Number: 471 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients Resistant to Biologic Therapy, Are They Different?
Adeeba Al-Herz¹, Aqeel Ghanem², Khulood Saleh³, Adel Al-Awadhi⁴, Waleed Al-Kandari³, Eman Hasan⁵, Mohammad Hussain⁵, Ibrahim Nahar², Fatemah Abutiban⁶, Ahmad Alenizi⁶, Yaser Ali², Ali Aldei¹, Hebah Alhajeri², Sawsan Hayat², Ahmad Khadrawy³, Ammad Fazal³, Khaled Mokaddem¹, Agaz Zaman², Ghada Mazloum², Youssef Bartella¹, Sally Hamed¹, Ramia Alsouk⁶ and Ahmed Al-Saber⁷, ¹Rheumatology, Al-Amiri Hospital, Kuwait city, Kuwait, ²Rheumatology, Mubarak Al-Kabeer Hospital, Hawally, Kuwait, ³Rheumatology, Farwania Hospital, Farwania, Kuwait, ⁴Faculty of Medicine, Kuwait, Kuwait, ⁵Al-Amiri Hospital, Kuwait city, Kuwait, ⁶Rheumatology, Jahra Hospital, Jahra, Kuwait, ⁷Department of Mathematics, Kuwait Technical College, Kuwait city, Kuwait
Background/Purpose: Patients with rheumatoid arthritis (RA) may fail to respond to biologic therapy. We study patients who are resistant to different classes of biologic agents…
Abstract Number: 472 • 2017 ACR/ARHP Annual Meeting
Viral Hepatitis Influences Patient Reported Outcomes Measures in Rheumatoid Arthritis
Suraj Timilsina¹, Harlan Sayles², Bryant R. England³, James R. O'Dell⁴, Ted R. Mikuls⁵ and Kaleb Michaud², ¹Division of Rheumatology & Immunology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁵Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Viral hepatitis may complicate the treatment of RA since select DMARD have the potential to cause hepatotoxicity or reactivation of latent viral infections. Whether…
Abstract Number: 473 • 2017 ACR/ARHP Annual Meeting
Medication Utilization Patterns of Rheumatoid Arthritis Patients Receiving Anti-TNF Infusion in Community Rheumatology Practices in the United States: Will Differences in Dosing and Administration Efficiencies between Intravenous Golimumab and Infliximab Have a Cost Impact for Payers?
Sergio Schwartzman¹, Lorie A. Ellis², Dennis Parenti³, Shawn Black³, Stephen Xu⁴, Wayne Langholff⁴ and Shelly Kafka³, ¹Weill Cornell Medical College, New York, NY, ²Janssen HECOR Immunology, Horsham, PA, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is an ongoing Phase 4 comparator study designed to provide a…
Abstract Number: 474 • 2017 ACR/ARHP Annual Meeting
Comparison of Tofacitinib Efficacy in Patients with Moderate Vs Severe Rheumatoid Arthritis: Pooled Analysis of Phase 3 Studies
Sergio Schwartzman¹, Prashanth Sunkureddi², Liza Takiya³, Mark Snyder³, Haiyun Fan⁴, Tatjana Lukic⁵, Jacqui Roberts⁶ and William F C Rigby⁷, ¹Hospital for Special Surgery, New York, NY, ²Clear Lake Rheumatology, Nassau Bay, TX, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Tadworth, United Kingdom, ⁷Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We evaluated tofacitinib 5 and 10 mg twice daily (BID)…
Abstract Number: 475 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patient Characteristics Also Predict Response to Therapy with Biologic Agents: Results from the Corrona Certain Study
Dimitrios A. Pappas¹, James Murray², Carol J. Etzel¹, David R Nelson², Bernice Gershenson³, Katherine C. Saunders¹, Sabrina Rebello¹ and Joel Kremer⁴, ¹Corrona, LLC, Southborough, MA, ²Eli Lilly and Company, Indianapolis, IN, ³University of Massachusetts Medical School, Worcester, MA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Response to biologic agents approved for RA may be associated with patient reported factors that are not related to disease and usually not included…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].